共 119 条
[1]
Kwekkeboom DJ(2001)[177Lu-DOTA0, Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients Eur J Nucl Med 28 1319-1325
[2]
Bakker WH(2010)In-Pentetreotide scintigraphy: procedure guidelines for tumour imaging Eur J Nucl Med Mol Imaging 37 1441-1448
[3]
Kooij PP(2007)What can gallium-68 PET add to receptor and molecular imaging? Eur J Nucl Med Mol Imaging 34 1897-1901
[4]
Konijnenberg MW(2011)“Reverse discordance” between 68Ga-DOTA-NOC PET/CT and 177Lu-DOTA-TATE posttherapy scan: the plausible explanations and its implications for high-dose therapy with radiolabeled somatostatin receptor analogs Nucl Med Commun 32 654-658
[5]
Srinivasan A(2011)Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors Oncology 80 326-329
[6]
Erion JL(2012)Is detection of additional lesions in post-peptide receptor radionuclide therapy scans with respect to diagnostic imaging only due to different affinity of ligands?: a report of discordance between diagnostic and posttherapy imaging using the same ligand Clin Nucl Med 37 817-818
[7]
Bombardieri E(2009)ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs Neuroendocrinology 90 220-226
[8]
Ambrosini V(2012)A potentially misleading finding at somatostatin receptor scintigraphy: focal pulmonary areas of intense accumulation without computed tomography-detectable lung lesions J Endocrinol Invest 35 708-709
[9]
Aktolun C(2011)Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours Endocr Relat Cancer 18 S27-S51
[10]
Baum RP(2010)Imaging of neuroendocrine tumours with gamma-emitting radiopharmaceuticals Q J Nucl Med Mol Imaging 54 3-15